To explore the therapeutic potential of rCCL17 in ICH, we administered recombinant CCL17 (rCCL17), a CCR4 ligand, intranasally to mice 1 h post‐ICH and evaluated its effects on neurological function, hematoma progression, brain edema, and microglial polarization. This evidence concerns the gene CCR4 and hematoma.